Jonathan Dickinson Takes the Helm at Innate Pharma
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced the appointment of Jonathan Dickinson as the new Chief Executive Officer (CEO) and Chairman of the Executive Board. The appointment reflects the company's commitment to leadership excellence as it prepares for exciting developments in immunotherapy.
A Seasoned Leader in Biotechnology
Before joining Innate Pharma, Jonathan Dickinson excelled as Executive Vice President and General Manager for Europe at Incyte, a prominent biotechnology firm. His career journey includes significant leadership roles at ARIAD Pharmaceuticals and Bristol-Myers Squibb, where he contributed to advancing oncology therapies. Notably, Dickinson’s 13 years at Hoffmann-La Roche were marked by substantial successes in developing pivotal oncology treatments.
Commitment to a Smooth Transition
Hervé Brailly, who has been serving as the interim CEO, will assist Dickinson during the transition to ensure continuity and stability within the company's operations. Brailly's experience as a co-founder and interim CEO will provide pivotal support during this leadership change.
The Vision for Innate Pharma
Irina Staatz-Granzer, Chairwoman of the Supervisory Board, expressed confidence in Dickinson's leadership, stating, "Jonathan is a distinguished industry leader whose extensive experience in biotechnology and pharmaceutical sectors make him the ideal choice to lead Innate Pharma. We are enthusiastic about his vision to advance our innovative immuno-oncology pipeline, propelling the company toward a promising future of growth and achievement."
In Dickinson’s own words: "Joining Innate Pharma is an exciting opportunity to lead a company that is paving the way in cancer treatment through harnessing the power of the immune system. I look forward to collaborating with my colleagues to propel our innovative therapies forward, enhancing patients' lives and generating value for our investors and stakeholders."
About Innate Pharma
Innate Pharma S.A. is a pioneering biotechnology company focused on developing advanced immunotherapies for cancer patients. The company's mission revolves around leveraging the innate immune system through a range of therapeutic approaches, including monoclonal antibodies and the proprietary ANKET platform, designed to facilitate multi-specific NK cell engagers.
Leading the Way in Cancer Treatment
Innate's lead program, lacutamab, targets advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas. The company collaborates with AstraZeneca on monalizumab for non-small cell lung cancer, while also exploring multiple ANKET drug candidates to tackle various tumor types.
Strategic Collaborations and Partnerships
To drive innovation, Innate Pharma collaborates with notable biopharmaceutical companies like Sanofi and AstraZeneca along with esteemed research institutions. These partnerships are aimed at accelerating research and development efforts centered around effective patient treatments.
Corporate Information
Innate Pharma is headquartered in Marseille, France, and maintains an office in Rockville, MD, USA. The company is publicly traded on Euronext Paris and the Nasdaq, highlighting its commitment to transparency and shareholder value.
This leadership change arrives at a pivotal moment, as Innate Pharma continues to push boundaries in treating cancer. With Jonathan Dickinson at the helm as CEO, the future of Innate Pharma looks promising.
Frequently Asked Questions
Who is the new CEO of Innate Pharma?
Jonathan Dickinson has been appointed as the new CEO and Chairman of the Executive Board of Innate Pharma.
What is Jonathan Dickinson's background?
Jonathan Dickinson has extensive experience in the biotechnology sector, previously serving as Executive Vice President and General Manager at Incyte.
What is Innate Pharma's focus?
Innate Pharma is dedicated to developing immunotherapies for cancer patients using innovative approaches such as monoclonal antibodies and NK cell engagers.
How does Innate Pharma collaborate with other companies?
Innate Pharma collaborates with leading biopharmaceutical companies like Sanofi and AstraZeneca to accelerate research and development for innovative cancer treatments.
Where is Innate Pharma headquartered?
Innate Pharma is headquartered in Marseille, France, and has a US office in Rockville, MD.
